## RHEUMATOID ARTHRITIS

## JAK-ing up inadequate RA therapy


For patients with rheumatoid arthritis (RA) that was active despite previous methotrexate therapy, the combination of tofacitinib plus methotrexate was as effective as adalimumab plus methotrexate in a head-to-head trial. However, tofacitinib monotherapy did not show non-inferiority to either combination therapy. "These results would suggest that in a group of patients who had an incomplete response to methotrexate, but who can tolerate methotrextate, it would be better to first add tofacitinib rather than to

switch to tofacitinib," explains corresponding author Roy Fleischmann.

The study, called ORAL Strategy, was a 1-year, phase 3b/4 randomized controlled trial that included patients at 194 centres in 25 countries. At 6 months, 46.0% (n = 173) of patients who were treated with the orally administered Janus kinase (JAK) inhibitor tofacitinib (5 mg twice daily) plus methotrexate achieved an ACR50 response, comparable to the 43.8% (n = 169) of those treated with adalimumab (40 mg every other week) plus methorexate



...tofacitinib plus methotrexate was as effective as adalimumab plus methotrexate in a head-to-head trial



Clinical trials are underway to assess whether methotrexate therapy could be withdrawn after a state of low disease activity has been achieved with the combination of tofacitinib and methotrexate. "If a patient does well with the combination," says Fleischmann, "then an attempt can be made to taper or discontinue methotrexate, with an expectation that a majority of patients will be able to do so."





ORIGINAL ARTICLE Fleischmann, R. et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, doubleblind, head-to-head, randomised controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)31618-5 (2017)

**FURTHER READING** Schwartz, D. M. et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. *Nat. Rev. Rheumatol.* **12**, 25–36 (2016)